|
⚲
|
| Keyboard |
| RTW Investments LP
✚
|
|
|---|---|
| CRD # | 153232 |
| SEC # | 801-78183 |
| CIK # | 0001493215 |
| AUM | 14.14 B (2026-03-30) |
| Employees | 70 (50% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 646-597-6980 |
| Address | 40 10th Avenue New York, NY 10014 |
| Source | [IAPD] [EDGAR] [Website] [LinkedIn] [Instagram] |
| Total AUM ($B) |
|---|
| In the News | |
|---|---|
| Thu, 23 Jul 2026 | RTW Investments swaps Allurion (ALUR) stock into pre-funded warrants — Stock Titan |
| Fri, 15 May 2026 | RTW Investments, Roderick Wong report 3.69M shares in Apellis (APLS) — Stock Titan |
| Fees and Compensation — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 5: Fees and Compensation Detailed information with respect to how RTW is compensated for the advisory services it provides is contained within the offering document for each Fund. Generally, RTW is compensated by the receipt of management fees and certain performance-based fees as described below. Prospective investors should carefully review the offering documents for the relevant investment vehicle prior to making an investment. As compensation for its services, RTW will generally receive a management fee in accordance with the offering documents. RTW will receive from the Flagship Fund an annual management fee of 2.00% or 1.25% of each Limited Partner’s Basic Capital Account and any Designated Capital Accounts (as those accounts are defined in the offering documents) to be collected on a monthly basis in advance (0.167% or 0.104%, respectively, to be collected per month). RTW will receive from the Innovation Fund an annual administrative allocation of 2.00% or1.25% of the net asset value of each Limited Partner’s Basic Capital Account and any Designated Capital Accounts (as those accounts are defined in the offering documents) to be collected RTW Investments, LP Form ADV Part 2A on a quarterly basis as of the last day of the fiscal quarter (0.50% or 0.3125%, respectively, to be collected per quarter), provided there were net profits equal to the applicable administrative allocation during that quarter. If all or a portion of the administrative allocation for any quarter has not been allocated due to insufficient net profits, the unallocated portion of such administrative allocation (the “Unallocated Amount”) will be rolled over and added to the administrative allocation for the following quarter and any future quarter. If there were a net loss for each of the immediately preceding four consecutive quarters, then the Unallocated Amount shall be reduced by the administrative allocation that was not made in respect of each of those four preceding consecutive quarters. For the avoidance of doubt, the administrative allocation is not subject to a loss carryforward and will be made even if the Innovation Fund is below its high-water mark. RTW will receive management fees from the Royalty Fund in an annual amount equal to (i) during the investment period which begins after the first investor closing (“Initial Closing”) and will end on the third anniversary of the Initial Closing (“the Investment Period”), the product of 2.0% and “Net Invested Capital” (generally, with respect to each investment, the lesser of cost and fair market value), and (ii) after the Investment Period, the product of 2.0% and Net Invested Capital. RTW will receive from the Biotech Opportunities Fund an annual management fee of 1.25% of the net asset value to be collected on a monthly basis in advance (0.104%, to be collected per month). The monthly management fee for the Flagship Fund and the Biotech Opportunities Fund, the quarterly administrative allocation for the Innovation Fund, and the quarterly management fee for the Royalty Fund will be drawn from the Flagship Fund, the Biotech Opportunities Fund, the Innovation Fund, and the Royalty Fund respectively, and paid or allocated to RTW. Management fees are deducted from the relevant Funds’ account by the applicable Funds’ administrator. At its sole discretion, RTW may elect to waive or modify the management fee or administrative allocation for investors who are members, partners, employees or affiliates of RTW, relatives of such persons and for certain strategic investors. RTW is responsible for all overhead expenses, including office rent; furniture and fixtures; stationery; secretarial/internal administrative services; salaries and bonuses; entertainment expenses; employee insurance and payroll taxes. All other expenses are paid by the Funds and include the management fees; expenses incurred in connection with identifying, evaluating, researching (including attending related industry conferences), structuring and negotiating proposed Fund investments (including those that are not ultimately consummated by the Funds), as well as research related travel and associated meals and entertainment; expenses associated with investment monitoring, such as meetings with portfolio company management teams (including meetings of the board of directors); the Funds’ organizational expenses; Fund- related compliance expenses; valuation expenses; brokers’ or other third-party deal sourcers’ fees and expenses (including retainers and similar fees and advancement of expenses), sales commissions and fees, commitment fees, non-refundable deposits and costs and expenses incurred in connection with the acquisition or disposition of actual or potential investments (whether or not consummated); principal and interest and fees, commissions, costs and expenses and other amounts payable related to or arising from any indebtedness, any subscription facility, guarantees or hedging activities of the Funds (including in connection with the negotiation and establishment of the relevant subscription facility, credit support or other relevant arrangements); costs related to the operations of the Funds, including, without limitation, fees, costs and expenses of any third-party administrator, software, experts, appraisers, custodians, outside counsel, advisors, bona fide consultants, accountants, auditors, tax return preparers and other professionals, including expenses associated with the preparation of the financial statements and tax returns and other tax filings of the Funds and its subsidiaries; expenses related to organizing, maintaining, operating, restructuring, winding up, liquidating and/or dissolving entities through or in which investments may be made (including any general partner (or equivalent) of such entities); taxes and other governmental ... |
| Account Minimums and Types of Clients — Form ADV Part 2A (3/30/2026) [Brochure] |
|---|
Item 7: Types of Clients The Firm’s clients are the Funds. The initial and additional subscription minimums for each Fund are disclosed in the offering documents which are provided to investors or prospective investors of the Funds. |
| Sector | Form 13F Holdings | Value ($B) | |
|---|---|---|---|
| Synta Pharmaceuticals Corp | 1.0 | ||
| Insmed Inc | 0.8 | ||
| Protagonist Therapeutics Inc | 0.5 | ||
| PTC Therapeutics Inc | 0.5 | ||
| Argenx SE | 0.5 | ||
| CG Oncology Inc | 0.5 | ||
| Celcuity Inc | 0.3 | ||
| BCTG Acquisition Corp | 0.3 | ||
| Erasca Inc | 0.3 | ||
| Natera Inc | 0.2 | ||
| View All | |||
| Holdings by Sector ($B) |
|---|
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | 4010 Royalty Investments ICAV | [2024-03-28] | 111.8 M | 284.4 M |
| Offered $111,770,000 · Filed 2025-04-29 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Duration More than one year · Commission $56,000 · Revenue Decline to Disclose | ||||
| HF | RTW Special Purpose Fund II LLC | [2019-11-04] | 16.4 M | 73.8 M |
| Filed 2019-11-18 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | RTW Special Purpose Fund I LLC | 2017-03-29 | 65.8 M | |
| HF | RTW Innovation Master Fund Ltd | [2016-03-30] | 918.4 M | 5,465.0 M |
| Filed 2025-07-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $10,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| HF | RTW Innovation Offshore Fund Ltd | 2016-03-30 | ||
| HF | RTW Innovation Onshore Fund LP | 2016-03-30 | 11.0 M | |
| HF | RTW Master Fund Ltd | [2012-10-31] | 1,985.8 M | 7,355.5 M |
| Filed 2025-07-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $10,000,000 · Remaining Indefinite · Duration More than one year · Commission $8,900,000 · Net Assets Decline to Disclose | ||||
| HF | RTW Offshore Fund One Ltd | [2012-10-31] | 1.5 M | 183.9 M |
| Offered $1,453,279 · Filed 2022-05-02 (D) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $10,000 · Duration One year or less · Revenue Decline to Disclose | ||||
| HF | RTW Onshore Fund One LP | [2012-10-31] | 1,584.4 M | 290.0 M |
| Filed 2025-07-15 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $10,000,000 · Remaining Indefinite · Duration More than one year · Commission $13,700,000 · Net Assets Decline to Disclose | ||||
| AUM Breakdown | Accounts | AUM ($B) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.0 |
| (b) Individuals (high net worth individuals) | 0 | 0.0 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 10 | 14.1 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 10 | 14.1 |
| By Discretionary | ||
| Discretionary | 10 | 14.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 10 | 14.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 6.8 | |
| United States Persons | 7.4 | |
| Total | 10 | 14.1 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Peter O'Leary | Director | 10 | 3 | |
| Jeffrey Brotman | Director | 6 | 3 | |
| Roderick Wong | Executive Officer | 14 | 2 | |
| Ef Capital Management | Executive Officer | 11 | 2 | |
| Rtw Fund Group GP LLC | Executive Officer, Promoter | 6 | 2 | |
| Rtw Investments LP | Promoter | 3 | 2 | |
| Agemian Patrick | Director | 2 | 2 | |
| Nathan Pelsma | Director | 2 | 2 | |
| 4010 Royalty Fund GP LLC | Promoter | 2 | 2 | |
| Dermot Hanley | Director | 2 | 2 | |
| View All | ||||
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001493215] | |
| 3 | [0001493215] | |
| 4 | [0001493215] | |
| SC 13D | [0001493215] | |
| SC 13G | [0001493215] |
| Firm Profile (Form ADV) | |
|---|---|
| Serves | Institutional |
| Fund Types | Hedge Fund, Private Equity |
| LEI | 54930058PPKTSERDV366 |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Allurion Technologies Inc ALUR
Common Stock, $0.0001 par value per share
|
2025-11-12 | Grant | 991,544 | $1.67 | 1,655,878 |
|
Allurion Technologies Inc ALUR
Common Stock, $0.0001 par value per share
|
2025-11-12 | Grant | 96,896 | $1.67 | 161,816 |
|
Allurion Technologies Inc ALUR
Warrant (Right to Buy) · derivative
|
2025-11-12 | Grant | 767,848 | ||
|
Allurion Technologies Inc ALUR
Warrant (Right to Buy) · derivative
|
2025-11-12 | Grant | 991,544 | ||
|
Allurion Technologies Inc ALUR
Warrant (Right to Buy) · derivative
|
2025-11-12 | Grant | 96,896 | ||
|
Allurion Technologies Inc ALUR
Common Stock, $0.0001 par value per share
|
2025-11-12 | Grant | 767,848 | $1.67 | 1,282,306 |
|
Allurion Technologies Inc ALUR
Common Stock, $0.0001 par value per share
|
2025-11-05 | Conversion | 822,722 | $3.35 | 2,756,119 |
|
Allurion Technologies Inc ALUR
Common Stock, $0.0001 par value per share
|
2025-11-05 | Conversion | 37,863 | $3.35 | 126,841 |
|
Allurion Technologies Inc ALUR
Common Stock, $0.0001 par value per share
|
2025-11-05 | Conversion | 631,954 | $3.35 | 2,117,046 |
|
Allurion Technologies Inc ALUR
Convertible Note · derivative
|
2025-11-05 | Grant | $126,839.00 | ||
|
Allurion Technologies Inc ALUR
Convertible Note · derivative
|
2025-11-05 | Conversion | $2,117,044.00 | ||
|
Allurion Technologies Inc ALUR
Convertible Note · derivative
|
2025-11-05 | Grant | $2,117,044.00 | ||
|
Allurion Technologies Inc ALUR
Convertible Note · derivative
|
2025-11-05 | Conversion | $2,756,117.00 | ||
|
Allurion Technologies Inc ALUR
Convertible Note · derivative
|
2025-11-05 | Grant | $2,756,117.00 | ||
|
Allurion Technologies Inc ALUR
Convertible Note · derivative
|
2025-11-05 | Conversion | $126,839.00 | ||
|
Health Sciences Acquisitions Corp 2 OBIO
Pre-Funded Warrants (Right to Buy) · derivative
|
2025-08-04 | Buy | 3,636,363 | $2.75 | 9,999,998 |
|
Health Sciences Acquisitions Corp 2 OBIO
Common Stock
|
2025-04-30 | Buy | 49,900 | $2.99 | 149,201 |
|
Health Sciences Acquisitions Corp 2 OBIO
Common Stock
|
2025-04-29 | Buy | 50,000 | $2.53 | 126,500 |
|
Allurion Technologies Inc ALUR
Common Stock, $0.0001 par value per share
|
2025-04-16 | Conversion | 822,722 | $3.35 | 2,756,119 |
|
Allurion Technologies Inc ALUR
Common Stock, $0.0001 par value per share
|
2025-04-16 | Conversion | 37,863 | $3.35 | 126,841 |
| showing 20 of 151 most recent transactions | |||||
| Comparable Firms | State | AUM |
|---|---|---|
|
Blackstone Ireland Limited
✚
|
15.19 B | |
|
Abry Partners II LLC
✚
|
MA | 14.90 B |
|
Napier Park Global Capital US LP
✚
|
NY | 14.57 B |
|
BSP NY LLC
✚
|
NY | 14.24 B |
|
SRS Investment Management LLC
✚
|
NY | 13.92 B |
|
Dynasty Wealth Management LLC
✚
|
FL | 13.88 B |
|
LibreMax Capital LLC
✚
|
NY | 13.87 B |
|
Avoro Capital Advisors LLC
✚
|
NY | 13.55 B |
|
Eagle Point Credit Management LLC
✚
|
CT | 13.24 B |
|
Post Advisory Group LLC
✚
|
CA | 13.03 B |